Bortezomib-High Dose Melphalan Conditioning for the Treatment of MM Patients Undergoing ASCT

被引：0
作者：
Jimenez-Zepeda, Victor [1 ]
Duggan, Peter [1 ]
Neri, Paola [2 ]
Chaudhry, Ahsan [3 ]
Tay, Jason [4 ]
Luider, Joanne [5 ]
Bahlis, Nizar J. [2 ,6 ]
机构：
[1] Tom Baker Canc Clin, Dept Med Oncol & Hematol, Calgary, AB, Canada
[2] Univ Calgary, Arnie Charbonneau Canc Inst, Calgary, AB, Canada
[3] Tom Baker Canc Clin, Calgary, AB, Canada
[4] Univ Calgary Tom Baker Canc Ctr, Calgary, AB, Canada
[5] Alberta Hlth Services, Calgary, AB, Canada
[6] Univ Calgary, Calgary, AB, Canada
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.2273.2273
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2273
引用
收藏
页数：5
相关论文
共 50 条
  • [41] BORTEZOMIB AND HIGH-DOSE MELPHALAN AS CONDITIONING REGIMEN BEFORE AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA: EXPERIENCE IN A UNIVERSITARY HOSPITAL
    de Miguel, D.
    Morales, D.
    San Roman, I.
    Golbano, N.
    Diaz, M.
    Arbeteta, J.
    Herrero, S.
    Subira, D.
    PInedo, B.
    HAEMATOLOGICA, 2012, 97 : 622 - 622
  • [42] Mini BEAM with Full-Dose of Melphalan (beaM) As a Conditioning Regimen for High Risk Patients with NHL Undergoing Autologous SCT
    Kalac, Matko
    Candland, Cristine
    Wallace, Lisa
    Gentner, Elizabeth
    Shah, Shreya
    Amengual, Jennifer E.
    Deng, Changchun
    Lentzsch, Suzanne
    O'Connor, Owen A.
    Mapara, Markus Y.
    BLOOD, 2016, 128 (22)
  • [43] Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study
    Roussel, Murielle
    Lauwers-Cances, Valerie
    Macro, Margaret
    Leleu, Xavier
    Royer, Bruno
    Hulin, Cyrille
    Karlin, Lionel
    Perrot, Aurore
    Touzeau, Cyrille
    Chretien, Marie-Lorraine
    Rigaudeau, Sophie
    Dib, Mamoun
    Nicolas-Virelizier, Emmanuelle
    Escoffre-Barbe, Martine
    Belhadj, Karim
    Mariette, Clara
    Stoppa, Anne-Marie
    Araujo, Carla
    Doyen, Chantal
    Fontan, Jean
    Kolb, Brigitte
    Garderet, Laurent
    Brechignac, Sabine
    Malfuson, Jean-Valere
    Jaccard, Arnaud
    Lenain, Pascal
    Borel, Cecile
    Hebraud, Benjamin
    Benbrahim, Omar
    Dorvaux, Veronique
    Manier, Salomon
    Augeul-Meunier, Karine
    Vekemans, Marie-Christiane
    Randriamalala, Edouard
    Chaoui, Driss
    Caers, Jo
    Chaleteix, Carine
    Benboubker, Lofti
    Vincent, Laure
    Glaisner, Sylvie
    Zunic, Patricia
    Slama, Borhane
    Eveillard, Jean-Richard
    Humbrecht-Kraut, Catherine
    Morel, Veronique
    Mineur, Philippe
    Eisenmann, Jean-Claude
    Demarquette, Helene
    Richez, Valentine
    Vignon, Marguerite
    BLOOD, 2022, 139 (18) : 2747 - 2757
  • [44] Salvage bortezomib-dexamethasone and high-dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT. A phase-2 trial
    Gimsing, P.
    Hjertner, O.
    Abildgaard, N.
    Andersen, N. F.
    Dahl, T. G.
    Gregersen, H.
    Klausen, T. W.
    Mellqvist, U-H
    Linder, O.
    Lindas, R.
    Clausen, N. Toffner
    Lenhoff, S.
    BONE MARROW TRANSPLANTATION, 2015, 50 (10) : 1306 - 1311
  • [45] Comparison of Melphalan Dose in Patients with Myelodysplastic Syndrome Undergoing Allogeneic Transplantation with Reduced-Intensity Conditioning
    Kurosawa, Shuhei
    Shimomura, Yoshimitsu
    Itonaga, Hidehiro
    Katayama, Yuta
    Onizuka, Makoto
    Tanaka, Masatsugu
    Kobayashi, Hikaru
    Ozawa, Yukiyasu
    Sawa, Masashi
    Kanda, Junya
    Doki, Noriko
    Fujisawa, Shin
    Uchida, Naoyuki
    Fukuda, Takahiro
    Atsuta, Yoshiko
    Ishiyama, Ken
    TRANSPLANTATION AND CELLULAR THERAPY, 2024, 30 (05): : 510e1 - 510e10
  • [46] Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy
    Nath, Christa E.
    Shaw, Peter J.
    Trotman, Judith
    Zeng, Lihua
    Duffull, Stephen B.
    Hegarty, Gareth
    McLachlan, Andrew J.
    Gurney, Howard
    Kerridge, Ian
    Kwan, Yiu Lam
    Presgrave, Peter
    Tiley, Campbell
    Joshua, Douglas
    Earl, John
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 69 (05) : 484 - 497
  • [47] Bortezomib and High Dose Melphalan (Bor-HDM) Compared to HDM Conditioning for the Treatment of Transplant Eligible Multiple Myeloma: Report from a Single Center
    Jimenez-Zepeda, Victor H.
    Duggan, Peter
    Neri, Paola
    Chaudhry, Ahsan
    Culham, Marcia
    Luider, Joanne
    Rashid-Kolvear, Fariborz
    Bahlis, Nizar J.
    BLOOD, 2015, 126 (23)
  • [48] Modified High-Dose versus High-Dose Melphalan Conditioning in Older Patients Undergoing Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis
    Hassan, Hamza
    Verma, Karina
    Ferri, Grace
    Brauneis, Dina
    Quillen, Karen
    Sloan, J. Mark
    Sanchorawala, Vaishali
    Edwards, Camille Vanessa
    TRANSPLANTATION AND CELLULAR THERAPY, 2022, 28 (11): : 761.e1 - 761.e7
  • [49] Full dose or reduced dose Melphalan (MEL) for autologous stem cell transplantation (ASCT) in multiple myeloma (MM): a single center analysis on 146 patients
    vom Hofe, F.
    Muegge, L-O
    Scholl, S.
    Hilgendorf, I
    Sayer, H.
    Yomade, O.
    Ernst, T.
    Hochhaus, A.
    von Lilienfeld-Toal, M.
    Brioli, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 184 - 184
  • [50] HIGH-DOSE MELPHALAN IS A SAFE CONDITIONING REGIMEN IN ELDERLY PATIENTS WITH MULTIPLE MYELOMA
    Cangini, D.
    Cerchione, C.
    Giannini, M. B.
    Di Battista, V.
    Frabetti, F.
    Petracci, E.
    Ronconi, S.
    Martinelli, G.
    HAEMATOLOGICA, 2019, 104 : 163 - 163
12345